Last Updated : January 26, 2021
Details
Generic Name:
talazoparib
Project Status:
Not filed
Therapeutic Area:
Breast cancer
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Talzenna
Project Line:
Reimbursement Review
Project Number:
N/A
Submission Type:
Non Submission
Indications:
Monotherapy for the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curative radiation or surgery) or metastatic breast cancer, who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting, unless patients were inappropriate for these treatments.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Last Updated : January 26, 2021